No Link — a 20% price control is optimal, increasing access without decreasing profits. Moshe Levy , business professors, Hebrew University, 2014, [School of Business, The Hebrew University, Jerusalem, Israel; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113894] We find that mild price regulation can substantially increase consumer surplus and the number of patients using the drug, while having only a second-order effect of the revenues of the pharmaceutical companies. For example, setting the price cap at